

Medilink Case Study

www.medilink.co.uk



Zilico Ltd APX 100



Sheffield based Zilico has developed a pioneering technology that offers a quicker, more accurate detection of cervical cancer in real time, removing several weeks of waiting for diagnosis

Cervical cancer affects around 500,000 women worldwide each year and is responsible for 300,000 deaths annually so the APX 100's ability to provide objective and accurate results in 'real-time' means it will offer a quicker diagnosis for both patients and clinicians worldwide.

Benefits

The APX 100 is a portable hand-held device that measures the resistivity of cells and detects any changes as they progress from normal through to cancerous.

It helps better manage the disease and significantly reduces morbidity from over-treatment due to false positives and under-treatment due to false negative smears.

Innovation

The APX 100 has been designed to combat this issue and enable colposcopists to better target biopsy sites helping to reduce the number of diagnostic biopsies and avoid the over-treatment of mild abnormalities.

The APX has undergone four separate clinical trials and is currently in the middle of an EU multi-centre trial. Once complete, the APX will be launched across the European Union.



Medilink
Yorkshire & Humber



Zilico Ltd

APX 100

Collaboration

Zilico has worked closely with Medilink Yorkshire & Humber (Y&H) to help raise the profile of their technology as well as exploring international opportunities, attending MEDICA for the last two years - the largest medical technologies fair in the world.

By showcasing their device on the Yorkshire Pavilion at MEDICA, with the support of Medilink Y&H and Yorkshire Forward, Zilico has been able to raise awareness of their technology among world-wide clinicians and source new worldwide partners who will sell their product once clinical trials have been completed.

“Export is invaluable for companies like Zilico and going to exhibitions like MEDICA with the support of Medilink Y&H and Yorkshire Forward offers an ideal opportunity for us to display our technology and seek worldwide sales and marketing partners.”

Sameer Kothari,
Chief Executive, Zilico Ltd

About Zilico Ltd

Zilico uses the technique of Electrical Impedance Spectroscopy (EIS) to examine tissue structure and also identify changes that are associated with progression to cancer.

This technology was developed by the University of Sheffield and allows clinicians to differentiate between normal, pre-cancerous and cancerous cells. Two applications of this technology are currently in development. The first is aimed at improving diagnosis in the colposcopy clinic, and the second targets the cervical screening process.

For more information visit www.zilico.co.uk



Medilink Yorkshire and Humber
Building 1
3 Smithy Wood Drive
Smithy Wood Business Park
Sheffield
S35 1QN

Tel: 0114 232 9292
Fax: 0114 245 6820
www.medilink.co.uk



Connect



Innovate



Communicate



Internationalise



Communities